Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP

	OMB APPROVAL								
	OMB Number:	3235-0287							
	Estimated average burden								
1	hours per responses	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Kendall Keith J					2. Issuer Name and Ticker or Trading Symbol Aquestive Therapeutics, Inc. [AQST]									(Che	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O AQUESTIVE THERAPEUTICS, INC. 30 TECHNOLOGY DRIVE						3. Date of Earliest Transaction (Month/Day/Year) 08/31/2019										Officer (give title below) CEO and		Other (s below)	·
(Street) WARREN NJ 07059 (City) (State) (Zip)				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - Non	า-Deriv	ative	e Se	curit	ies Ac	quired,	Dis	posed c	of, or B	enef	icially	/ Owned				
			2. Transaction Date (Month/Day/Year)		ear)	2A. Deemed Execution Date, if any (Month/Day/Year)		Code	Transaction Code (Instr.		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)				es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) (D)	or F	Price	Reported Transact (Instr. 3	ion(s)			(Instr. 4)
Common Stock 08/31					1/201	/2019		M ⁽¹⁾		14,57	72 <i>A</i>	A	\$0	669,153			D		
Common Stock 08/3					1/2019			F ⁽²⁾		6,67	6 I		\$3.8	662	52,477		D		
		7	Fable II - I								osed of onverti				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	Date, T	4. Transaction Code (Instr 8)				6. Date E Expiratio (Month/D	n Date	of Secu Underly Derivat		itle and Amount Securities Ierlying Ivative Security Itr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transactie (Instr. 4)	Owne Form: Direct or Ind (I) (Ins	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				c	Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	or Nui of	nount mber ares					
Restricted Stock Units	\$0	08/31/2019		ı	M ⁽¹⁾			14,572	08/31/20	19	(3)	Common	1 14	,572	\$0	43,71	6	D	

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- 2. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability.
- 3. There are no expiration dates on RSUs.

Remarks:

/s/ Robert Arnold, as Attorney-In-Fact

09/03/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.